Small Bowel Organ Regeneration
The primary function of small bowel is the processing and absorption of nutrients from ingested food. Loss of bowel can result in malabsorption and when the loss of small bowel is greater than 80% it is associated with increased requirement for parenteral nutrition support (essential nutrition administered intravenously), with associated increased morbidities and decreased overall patient survival. Not only is this a major impediment to quality of life, but is also life threatening and a large financial burden for healthcare systems.
Bowel diseases, such as necrotising enterocolitis in infants and Crohn’s disease in adults, are diseases which can lead to short bowel syndrome (SBS) with an estimated 5 year cost of treating SBS in infants >£1 million per patient. Bowel transplantation is a potential option, but it is a complicated procedure which is infrequently performed with only 50%-60% survival rate at 5 years.
By providing a small bowel replacement, Videregen aims to improve patient outcomes and quality of life while alleviating the associated ongoing healthcare costs for those patients with SBS. Videregen’s solution is to decellularise porcine small bowel, which is similar in both size and anatomy to human small bowel, to remove all cells and cellular remnants, leaving a purified biological bowel scaffold.
The purified bowel will then be seeded with the patients own stem cells, before implanting the cell seeded bowel into the patient. Since the replacement bowel has the patients own cells, there will be no need for additional expensive immunosuppressant drugs.